Perioperative Management of Hemophilia A Using Recombinant Factor VIII in Patients Undergoing Major or Minor Surgery by Okamoto, Atsushi et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Perioperative Management of 
Hemophilia A Using Recombinant 
Factor VIII in Patients Undergoing 
Major or Minor Surgery
Atsushi Okamoto, Kenta Yamamoto, Go Eguchi, 
Yoshitaka Kanai, Terufumi Yamaguchi and Yasuhiro Maeda
Abstract
Among the surgical treatments performed in patients with hemophilia, 
joint surgery for intra-articular bleeding is the most time-consuming. Previous 
reports describe the perioperative management of hemophiliacs undergoing 
coronary artery bypass grafting or of those undergoing cystectomy for treatment 
of hematuria. In the former study, the patient was elderly; in the latter study, the 
authors concluded that cystectomy in hemophiliacs is safe if monitored appro-
priately and that urinary diversion using the intestine should be avoided because 
anastomotic hemorrhaging may occur. In this study, we discuss coagulation 
factor replacement therapy for patient with hemophilia A undergoing major or 
minor surgery.
Keywords: hemophilia, hemophilia with inhibitors, perioperative management,  
joint surgery
1. Introduction
Due to advancements in coagulation factor preparations, hemophilia treat-
ment has progressed from conventional bleeding replacement therapy to periodic 
replacement therapy. Historically, the aim has been to perform symptomatic treat-
ment, but currently, the aim of treatment is preventive. Due to bleeding incidents 
that are characteristic of hemophilia, control of bleeding is particularly important 
for perioperative patient management. The indication for surgical treatment in 
patients with hemophilia includes diseases caused by bleeding related to hemophilia 
as well as those not related to hemophilia. The number of surgeries involving 
patients with hemophilia is increasing annually.
Due to the development of hemostatic hemostasis treatments, obstacles due to 
bleeding in young patients are decreasing. However, surgical cases are increasing 
due to the trend in applying surgery to disorders, which have conventionally been 
treated nonsurgically and due to an increase in the number of aging patients as a 
result of improved life expectancy. Due to the reasons stated above, we consider 
that it is important to stay informed about the latest developments in the periopera-
tive management of patients with hemophilia.
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2. Preoperative preparation
Preoperative preparation for hemophiliac patients involves a thorough review 
of various aspects of the patient’s condition. The first parameter to be ascertained 
is whether the hemophilia is of type A or type B. Following this, the severity of 
hemophilia needs to be confirmed. Hemophilia is classified based on the blood level 
of coagulation factors such as factor VIII or factor IX; the disease is characterized 
as severe when the blood coagulation factor level is less than 1%, moderate if it is 
1–5%, and mild if the level is 5% or more. Severity of daily symptoms is generally 
accepted to reflect the severity of the disease. In patients receiving prophylactic 
replacement therapy, it is usually necessary to confirm details such as how many 
units are being administered and how the preparation is being self-injected. The 
presence of inhibitors (alloantibodies) in the blood needs to be checked as part of 
the preoperative preparation as well. Although it is known that patients with severe 
hemophilia are more likely to have developed inhibitors, genetic mutations are 
known to cause inhibitor formation even in cases with mild disease. Among patients 
who have received prior treatment, it is also important to check for HCV or HIV 
infections. Furthermore, if a chronic HCV infection is incident, liver cirrhosis or 
liver cancer may occur concomitantly, and it is thus necessary to screen patients for 
these conditions. The abovementioned points may be used as a checklist to evaluate 
the suitability of patients for surgical procedures. If the abovementioned evalua-
tions reveal no issues, surgery may be performed as per usual protocol. Depending 
on the magnitude of the surgical invasion, a treatment plan may then be set up, 
detailing the target levels and of coagulation factors to be maintained, and the dura-
tion for which the levels need to be maintained. Regarding treatment planning, it is 
necessary to administer a necessary and sufficient amount of a coagulation factor 
preparation to prevent hemorrhagic complications. However, it should also be noted 
that an overdose of coagulation factor preparations can lead to a risk of thrombosis. 
The clearance of the coagulation factor preparation varies greatly among patients. 
In view of this fact, a pharmacokinetic test of factor VIII factor/factor IX prepara-
tions ideally to be used for surgery may be conducted preoperatively. Accurate 
pharmacokinetic profiles may be obtained by measuring coagulation factor activ-
ity before administration of the preparation, and 15 minutes, 1, 2, 4, 8, 12, and 
24 hours after administration; such an evaluation allows for a proper understanding 
of the recovery rate and the half-life of the administered factors [1].
3. Selection of coagulation factor replenishment method
There are two main methods of administration of coagulation factor replace-
ment therapy during surgery. The first method is a bolus administration method (BI 
method), which involves repeated administration of a bolus injections. The second is 
the continuous administration method (CI method) in which a syringe pump continu-
ously administers coagulation factors after an initial bolus administration. Historically, 
the stability of the formulations used for coagulation factors has been poor; such 
formulations needed to be administered as soon as they were thawed. Therefore, 
perioperative management was predominantly performed using the BI method. In the 
BI method, when the coagulation factor is injected, the coagulation factor level in the 
blood exceeds 100% and gradually falls thereafter; when the level approaches 50%, 
the next bolus is administered. Bolus administration is repeated each time the blood 
coagulation factor level approaches 50%. The BI method has the advantage of being 
simple, although the associated disadvantage is that fluctuation in the coagulation 
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factor levels is high. Intraoperative and postoperative bleeding in recurrent invasive 
surgery and reoperation is also a serious issue. Recently, however, the stability of the 
drug and the reliability of the syringe pump have been improved significantly, and the 
CI method is currently the recommended method for use during major surgery. Using 
the CI method, the blood clotting ability of hemophilia patients without inhibitors may 
be restored to that of non-hemophiliac subjects, so that the indication for surgery can 
be adjusted to the same level as that for non-hemophiliac subjects. Scientific evidence 
for the effectiveness of the CI method has been accumulating, and there are many 
reports of surgical cases in which the CI method has been used. However, because 
the CI method requires specialized expertise, it is desirable to conduct this procedure 
under the guidance of a hemophilia specialist. The BI and the CI methods have distinct 
advantages and disadvantages. For routine surgical operations predicted to have less 
bleeding volume, selection of the BI method according to the situation of the clinical 
site is appropriate. There have been few systematic studies of the BI method, and hence 
it cannot be officially recommended. However, as mentioned above, this method has 
historically been used extensively for numerous types of surgical procedures. The most 
important advantage of the BI method is that it is a simple method. Application of this 
method in emergency situations should be decided based on the trough value of the 
coagulation factor concentration in the blood or when there is insufficient prepara-
tion time and insufficient experience with the CI method. If the staff is experienced 
in performing the CI method, this method may be applied in emergency situations; 
a provisional administration speed may be used while assuming a coagulation factor 
concentration of 100%. However, since the optimal administration rate varies greatly 
among individuals, it is better to monitor the activated partial thromboplastin time 
(APTT) and the coagulation factor concentration at an early stage. It is also important 
to check the status of syringe pumps and tubes regularly. Regardless of which method 
is chosen, when there is a large amount of bleeding, it is necessary not only to supple-
ment the deficient factor but also to replenish other coagulation factors as well as 
healthy subjects. It is important to understand the advantages and disadvantages of the 
BI and the CI methods, so as to adopt the method suitable for the individual clinical 
site and as per the reference guidelines.
4.  Important considerations for the use of the continuous  
administration (CI) method
Even if the target coagulation factor level is set and perioperative management 
with CI method is executed as planned, the coagulation factor level may not rise 
as expected. The reason for this may be that the coagulation factor adheres to the 
surface of the drip tube wall and the assumed dose is not administered. Since 
the formulations currently used do not include proteins such as albumin, there 
is a possibility that coagulation factors are lost due to being adsorbed on the tube 
wall surface when diluted. Therefore, in the case of the CI method, it is necessary 
to perform injections from the side tube as close to the patient side of the line as 
possible. During implementation of the CI method, the coagulation factor formula-
tion is placed at room temperature for several hours; this implies that this protein 
preparation is placed in a harsh environment for an extended period, which makes 
it difficult to determine the dilution of the preparation and the exact amount that 
the patient receives. Since the amount of coagulation factor contained in one vial is 
large, if the preparation is intended to be administered continuously at the deter-
mined concentration, the flow rate is usually adjusted to be low, which may result in 
clogging of the tubes. In order to solve this problem, the use of a low-concentration 
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formulation such as that of 250 or 500 units is advised. We conclude that the CI 
method can be performed relatively safely by carefully selecting the appropriate 
formulation.
5. Intraoperative and postoperative management
Measurement of APTT and factor VIII activity is the most common measure-
ment performed during surgery and postoperative procedures. However, in many 
institutions, there is delay in obtaining the results of the factor VIII activity tests 
after sample submission, and thus, APTT is considered to be the most useful way to 
monitor patient condition, especially during surgery. APTT is helpful if there is not 
much bleeding. However, if the coagulation factor activity other than that of factor 
VIII decreases, such as when significant bleeding occurs, APTT may not be normal-
ized even if factor VIII is adequately administered. Changes in APTT are thus dif-
ficult to interpret, since APTT is affected by the magnitude of the bleeding volume 
and also by the degree of liver cirrhosis. However, whether the APTT is within the 
control level can be evaluated, unless it is extremely extended. In cases where it is 
not possible to obtain hemostasis either intraoperatively or after surgery despite 
administration of factors VIII and IX, hemophilia may be assumed as the cause, and 
treatment for this condition may be instituted. If coagulation factor activities other 
than those of factor VIII and factor IX are low as in splenectomy for cirrhosis of the 
liver or when the amount of bleeding is large, levels of other coagulation factors 
may also decrease. Therefore, when and how much fresh frozen plasma (FFP) is 
administered should be considered separately.
6. Joint surgery
Due to recent advancements in coagulation factor replacement therapy, it is 
now possible to prevent intra-articular bleeding right from infancy in children with 
hemophilia. It is thus possible to prevent escalation of hemophilic arthropathy in 
such children. On the other hand, if hemophilic synovitis has already occurred 
and several joints show intra-articular bleeding, arthropathy cannot be prevented, 
and its progress becomes an issue of concern. In joints with advanced arthropathy, 
degeneration cannot be avoided, even if subsequent bleeding can be completely 
prevented. Such degeneration of joints is a major cause of physical dysfunction in 
adult hemophilia patients. Hemophilic arthropathy is commonly seen in the joints 
of the elbows, knees, and ankles; in particular, dysfunction of lower limb joints 
greatly affects daily life. Orthopedic treatments for hemophilic arthropathy include 
measures against intra-articular bleeding, synovitis, and arthropathy. Specific 
orthopedic treatments are performed for treating synovitis, such as joint puncture, 
washing, bleeding, synovial membrane resection for the blood remaining in joints, 
synovial membrane resection and arthrosis, and artificial joint replacement or 
arthrodesis. Joint puncture and washing are useful treatment methods and are 
possible outpatient procedures. In the following sections, we discuss synovectomy, 
artificial joints, and joint fixation in more detail.
7. Synovectomy
Joints that show recurrent intra-articular bleeding on diagnostic images but do 
not show arthropathy are the best indications for synovial resection. There are two 
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major methods of synovectomy, namely, arthroscopic synovectomy (AS) and open 
synovectomy. Synovial restoration is a method of restoring the synovial membrane 
by injecting chemical substances (mainly corticosteroids and antibiotics) and 
radioactive isotopes into joints. Chemical synoviothesis uses chemical substances 
and results in severe joint pain after the injection; additionally, it is ineffective 
despite multiple injections to the joints. However, because it is inexpensive, it is 
frequently performed in developing countries. Radioactive isotope synovectomy 
(radioactive synoviothesis) is a treatment that can be expected to be effective with 
a single intra-articular injection, and it is internationally positioned as the first-line 
therapy for treatment of hemophilic arthritis. In this therapy modality, only beta 
rays with a shallow arrival depth are generated, and nuclides with a very short 
half-life are used. The effect of radioactive synoviothesis on genetic material and 
the articular cartilage have been reported by several publications, and its safety 
has been reviewed. However, two cases of leukemia have occurred after synovec-
tomy using P32-labeled radionuclides [2], and in 2010, the Medical and Scientific 
Advisory Council (MASDAC) issued a cautionary note against the application of 
radioactive isotopes for synovial treatment [3]. Since arthroscopic synovectomy 
requires hospitalization and the use of adequate coagulation factor preparations, it 
is generally applied in cases where at least three cycles of radioactive synoviothesis 
have been ineffective. However, in Japan, arthroscopic synovectomy is the first 
choice of treatment. An advantage of this method is that other treatments can be 
added to the treatment regimen; in addition, this method also allows for the obser-
vation of the joint surface. It is recommended that arthroscopic synovectomy be 
performed even in early arthropathy. Invasive synovectomy is a surgical procedure 
which involves opening the joint capsule and observing the joint under direct 
vision, so that a wide expanse of the synovium can be removed in a short time. 
However, the degree of bleeding also increases, and administration of coagulation 
factor preparations may be necessary to enable installation of artificial joints. In 
addition, there is also a high risk of contracture after surgery, and thus, this proce-
dure is not frequently performed.
8. Purpose and significance of synovectomy
Intra-articular bleeding caused by severe hemophilia leads to severe swell-
ing of the joints, and the mobility of the affected limb is limited due to pain. 
When bleeding events happen repeatedly, the synovial membrane proliferates. 
Treating hematomas and hemosiderin that occur in joints provides relief, but the 
blood vessels may re-appear on the synovial membrane; the synovial membrane 
assumes a villous shape and bleeds easily in such conditions. A vicious circle may be 
established in which synovial proliferation worsens as bleeding events occur more 
frequently. The joint, which shows repeated bleeding events, is called a target joint, 
and the ankle and knee joints in the lower limb and the elbow joint in the upper 
limb are commonly observed to be target joints. Chronic synovitis eventually causes 
articular cartilage and subchondral bone erosion and degeneration, resulting in a 
condition called hemophilic arthropathy. The patient does not use the affected limb 
either consciously or unconsciously due to pain avoidance, and the functional dete-
rioration progresses with increasing intensity in combination with muscle weakness 
[4]. Synovial resection is one way to break this vicious circle. As mentioned above, 
synovial tissue, which shows a villous configuration, bleeds easily; however, if such 
tissue is surgically removed and appropriate hemostasis is maintained in conjunc-
tion with coagulation management, joints can be restored to a state in which they 
do not easily bleed. However, since synovial excision cannot be recommended until 
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cartilage damage is observed or compatible destroyed joint repair, there are few 
therapeutic options for highly advanced severe hemophilic arthropathy. Treatment 
in early-stage hemophilic arthropathy is aimed at providing pain relief by reducing 
the bleeding frequency; further, this treatment is also applied to delay the progres-
sion of arthropathy. However, since the elbow joint does not always receive a high 
load as compared with the joints of the lower limbs such as the knee joints, if the 
range of motion can be maintained with little pain or bleeding, synovial ablation is 
significantly beneficial. Synovial ablation is a good treatment option especially for 
young people with excellent bone neogenesis and tissue remodeling ability; in this 
patient population, remodeling may occur on the joint surface depending on the site 
and stage, and joint repair may also take place to some extent [5, 6].
9. Surgical methods
9.1 Direct surgery
Although different approaches exist for joint surgery, joint synovectomy under 
direct vision is a common orthopedic surgical procedure and requires no special 
techniques or instruments. However, post-surgery, synovial membrane remnants 
may facilitate the recurrence of intra-articular bleeding; surgical removal of 
the synovial membrane in the joint may also lead to joint contracture caused by 
postoperative scar formation. In the case of the elbow, if a thorough resection of 
the synovial membrane in the joint is attempted, the radial head may also have 
to be removed; both internal and external approaches to the joint may have to be 
explored. Although there are few opportunities for joint hemorrhage after surgery 
and hence patient activity increases, there are few things that may improve elbow 
flexion and extension range. Improvement of forearm restraint can be expected if 
radial head resection is also performed [7].
9.2 Arthroscopic surgery
Arthroscopy is a surgical procedure that allows surgical access to joints in a 
minimally invasive fashion and was introduced in the 1940s. Surgical procedures 
have benefited from advancements in hardware such as cameras, monitors, and 
surgical instruments. Because there is less damage to the surrounding joint tissues, 
arthroscopic surgery results in fewer contractures as compared to under-sight 
surgery. Due to the presence of critically important neural blood vessel bundles 
surrounding joints, a strong knowledge of anatomy and technical proficiency are 
required to perform this surgical procedure. However, if done well, synovial resec-
tion with arthroscopy can be as effective as or more effective than that performed 
under direct vision; additionally, as mentioned above, there is little contracture 
after surgery. Therefore, arthroscopic surgery is recommended for surgical syno-
vectomy of the hemophilic elbow joint [8].
9.2.1 Elbow arthroscopic surgery
The elbow joint has a complicated structure in which the upper and side surfaces 
of the radius are in contact with the hinge joint (called the arm slider). In order to 
remove all proliferating synovial membranes in this joint cavity, three parts need to 
be approached: the anterior, posterior, and the radial parts. It is necessary to create 
at least two portals for inserting the arthroscope and other instruments such as a 
shaver. Surgery is performed after the arthroscope and other instruments have been 
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placed properly. Using the abovementioned portal, instruments such as a shaver 
and a high frequency cautery/transpiration device are employed for performing 
the surgery. In hemophilic arthropathy, the synovial membrane appears yellow-
ish brown due to hemosiderin deposition caused by repetitive bleeding; the blood 
vessels in the synovial membrane proliferate significantly in the acute inflammatory 
phase and bleed easily. However, if the exposed blood vessels are cauterized intra-
operatively, the surgery itself is comparable to a conventional synovectomy. It is 
impossible to surgically remove 100% of the synovial membrane; at the elbow joint, 
this membrane often grows around both side margins of the wrist joint and around 
the radial neck. MRI imaging of the synovial membrane is thus performed before 
surgery, so that a comprehensive resection of the synovium may be achieved to the 
extent possible. At the end of surgery, one of the portals is used to indwell a closed-
type drain in the joint, and the blood in the joint is aspirated and discharged. The 
drain is removed at about 48–72 hours post-surgery, which is slightly longer than 
that for conventional arthroscopic surgery.
10. Perioperative hemostasis/coagulation management in synovectomy
Coagulation factor supplementation is frequently performed before surgery, and 
the aim is strict hemostasis/coagulation management, so that intra-articular bleed-
ing is prevented during the perioperative period. Synovectomy is also specifically 
aimed at reducing the frequency of intra-articular bleeding. Perioperative bleeding 
causes synovial proliferation in the joints leading to recurrent bleeding episodes; 
hence, it is desirable to adequately replenish coagulation factors while monitoring 
clotting factors and hemostatic and coagulation parameters.
11. Artificial joint replacement
Indications for artificial joint replacement include (1) late-stage arthropathy, 
(2) serious disruption in activities of daily living (ADL) due to arthropathy, and (3) 
adults (epiphyseal line is closed). The three points mentioned above are important 
for patient selection. For the clinical evaluation of late-stage hemophilic arthropa-
thy, the same criteria as applied for osteoarthritis can be accepted. While effect on 
ADL is an important selection criterion, ADL parameters are highly subjective. 
Therefore, it is necessary to discuss before surgery whether the patient’s desired 
postoperative life level can be secured. In adult hemophilia patients, it is necessary 
to explain that when multiple joints develop terminal arthropathy, multiple joint 
surgeries need to be performed. Artificial joints are usually installed in those aged 
60 years or older, and at this age, re-replacement surgery may not be required. 
However, in some hemophilia cases, patients are forced to use a wheelchair from the 
age of 20 years, because of pain from arthritis. While artificial joint replacement 
surgery in young patients does not address the underlying arthritic condition, this 
surgery nevertheless becomes a necessity to improve QOL. It is important to note 
that performing re-replacement surgeries repeatedly is not feasible and performing 
artificial joint replacement may just postpone the occurrence of joint problems. 
However, in our opinion, living in a wheelchair in the older age may be an accept-
able way of maintaining a patient’s QOL, if an active lifestyle is facilitated for the 
patient during the young-to-mature years. For this reason, it may be better to per-
form artificial joint replacement even in young patients, based on the case details. 
The most important reason to perform artificial joint replacement is to eliminate 
or alleviate pain. Simultaneous synovectomy is also performed for cases with joint 
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hemorrhage, so as to stop or reduce the number of bleeding events. On the other 
hand, the knee joint has been reported to show poor improvement in range of 
motion. For this reason, postoperative rehabilitation is important.
12. Arthrodesis
Arthrodesis involves surgically immobilizing affected joints. By sacrificing the 
range of motion of the joint, this procedure treats joint pain and intra-articular 
bleeding. This procedure is performed primarily on the ankle joint. In the natural 
course of hemophilic ankylosis, the joints appear stark on diagnostic images in the 
terminal stage. Therefore, surgery to fix joints artificially is not actively carried out, 
and numerous parameters are monitored while the patient is administered with 
symptomatic treatment. Arthrodesis has recently been reviewed as a method for 
treating artificial ankle joints. Although the treatment protocol varies depending on 
the facility, if only one side presents with terminal arthrosis, the joint function can 
be compensated by the other healthy side, so that joint fixation is applied. If ankle 
joints on both sides are candidates for artificial ankle joint replacement, this condi-
tion is an indication for artificial ankle replacement.
13. Problems other than hemostasis in joint surgery
13.1 Preoperative examination and anesthesia management
Spinal anesthesia has been conventionally contraindicated as a method of anes-
thesia in hemophiliac patients, and surgery has been performed with general anes-
thesia. The reason is that when the spinal venous plexus is damaged at the needle 
tip of the lumbar puncture needle, if the coagulation is insufficient, hemorrhage 
is prolonged and may lead to a deep hematoma; the discovery of such a hematoma 
is liable to be delayed due to the depth of the location. If such a hematoma occurs, 
there is a high risk for spinal cord injury. With modern hemostatic management 
methods, it is possible to maintain the levels of coagulation factors adequately while 
concurrently administering spinal anesthesia, and if persistent subdural anesthesia 
can be performed, it is effective for postoperative pain management. However, 
while very few institutions use spinal anesthesia during surgery in patients with 
hemophilia, most perform surgery with general anesthesia. There is no relevance 
of hemophiliac status on the choice of anesthetics. However, depending on the type 
of antiviral drugs used for people infected with HIV, care should be taken because 
some drugs inhibit the metabolism of anesthetics and increase the required dosage.
13.2 Surgery in HCV- and HIV-infected patients
Some patients who undergo orthopedic surgery (especially that of artificial 
knee replacement) show co-occurring HCV or HIV infections due to phytotoxicity. 
While a proportion of patients with successful treatments (e.g., interferon therapy) 
no longer have HCV infections, many patients show progression to liver cancer 
or liver cirrhosis due to long disease duration. In contrast, though symptomatic 
improvement may be achieved with the latest antiviral drugs in HIV-infected 
patients, a cure is not possible. Particularly with respect to hepatitis C, postopera-
tive death cases are significantly higher among cases characterized as Child classifi-
cation B, those with low ascites and albumin, and those with thrombocytopenia [9]. 
Confirmation of these conditions is important for surgical decisions.
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13.3 Prevention of deep venous thrombosis (DVT)
Lower extremity artificial joint surgery is one of the risk factors for deep venous 
thrombosis (DVT), and DVT risk is of particular relevance in hemophilia patients. 
However, most hemophilia patients undergoing artificial joint replacement surgery 
are adolescents on anti-inflammatory analgesic therapy and show no other comor-
bidities that may influence thrombus development. Therefore, the risk of DVT 
occurrence due to lower extremity artificial joint surgery may be lower than that 
due to general lower limb prosthesis replacement surgery. However, it was reported 
that among asymptomatic patients, DVT was detected by lower limb ultrasonogra-
phy in 10% of cases after surgery, even in patients with hemophilia [10]. A previous 
report has suggested that in addition to physical methods such as application of 
elastic stockings and intermittent pneumatic compression, anticoagulation therapy 
is administered at about half of the facilities where the survey was conducted 
[11]. Either way, even in patients with hemophilia, physicians must be alert to the 
development of postoperative DVT, and timely cessation of prescribed bed rest and 
early rehabilitation are important.
14. Latest findings due to the appearance of half-life extended drugs
The development of coagulation factor preparations is one of the most impor-
tant factors impacting the prognosis and quality of life of patients with hemophilia. 
Recent advancements in extending the half-life of drugs using various mechanisms 
have attracted much attention. Such extended half-life formulations make it pos-
sible to reduce the frequency of self-injections even in regular prophylaxis therapy 
and reduce the frequency of bleeding symptoms (such as bleeding in the joints and 
muscles). In addition, such advancements not only extend the half-life and improve 
the stability of the drugs; they also impact patient burden by reducing the number 
of required hospital visits. Various benefits have been obtained from the use of 
half-life extended drugs, and this development has brought about major changes in 
the treatment of hemophilia. However, since half-life extended medicines are short, 
there is a lack of substantial evidence of the efficacy in perioperative administration 
regimens. Moreover, the number of cases in which these drugs have been used is too 
small for inclusion in case report studies. In this regard, we have experienced and 
reported a case of perioperative management of hemophilia A using efraloctocog 
alfa (ELOCTATE®) during endoscopic nasal pituitary adenomectomy for growth 
hormone-producing pituitary adenoma. There are no other reports of the successful 
use of ELOCTATE (a drug with an extended half-life) in conjunction with the BI 
method for a major surgery. We summarize below details of the case study [12]. A 
28-year-old man was admitted to our hospital due to bulging of the glabella. He had 
first noticed the bulging of the glabella in 2013. He was aware of the enlargement 
of his fingers and the size of his shoes since August 2016, and he was now seeking 
medical attention. He was referred to the department of endocrinology and metab-
olism at our hospital with suspected acromegaly. A diagnosis of growth hormone-
producing pituitary adenoma was made by performing several tests, including a 
brain MRI and loading tests. Furthermore, we decided to perform endoscopic nasal 
pituitary adenomectomy at our department of neurosurgery. The patient clinical 
history included hemophilia A, pediatric asthma, and hypothyroidism.
Hemophilia A was diagnosed as moderate in infancy. The patient reported self-
injecting rurioctocog alfa (trade name: ADVATE®) two to three times a week for 
hemophilia. The final bleeding episode occurred in the left knee joint in April 2013 
and required hospitalization for 3 days. Factor VIII inhibitors were not detectable in 
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the patient’s blood. We prepared a regimen for administration of rFVIIIFc in accor-
dance with guidelines for hemostasis treatment for hemophilia patients without 
inhibitors (Revision 2013, published by the Japanese society of Thrombosis and 
Hemostasis). At our hospital, the results of factor VIII activity cannot be obtained 
promptly, so in the perioperative period, we monitored APTT in lieu of factor 
VIII levels in sera. From day 2 onward, we injected rFVIIIFc intravenously at 2 PM 
daily and measured APTT and factor VIII activity at 6 AM the following morning 
(16 hours after intravenous injection). A blood test was conducted to measure 
APTT and factor VIII activity at 6 AM on surgery day. On the day of the surgery, 
4000 IU of rFVIIIFc were intravenously injected at 8 AM (1 hour before leaving the 
ward for the surgery), and APTT and factor VIII activity were measured again after 
15 minutes of intravenous injection (because peak levels of rFVIIIFc in the blood are 
achieved approximately 15 minutes after intravenous injection). APTT at this time 
was assumed to be a function primarily of factor VIII activity and was used as the 
most important index in perioperative control. The surgery began at 10:14 AM and 
ended at 1:39 PM (3 hours and 25 minutes). The surgery performed was an endo-
scopic nasal pituitary adenomectomy. The volume of bleeding during the surgery 
was 150 ml and was in close agreement with the expected volume of bleeding. Prior 
to surgery, a risk of bleeding from the nasal mucosa was suspected; however, only 
two mild nasal bleeding events were confirmed and were resolved adequately. The 
patient was discharged on day 13, on schedule. Thus, perioperative management 
using drugs with an extended half-life can be applied to control hemostasis/coagu-
lation at the perioperative stage using the BI method even for major surgery, as in 
the case described above. The advantage of perioperative management by the BI 
method using half-life extended drugs is that these drugs need to be administered 
through intravenous injection only once a day, and such a treatment protocol is 
easy to perform at a hospital. Furthermore, the BI method is also economical as it 
reduces the amount and thus the cost of the drug, as compared with the CI method 
using the existing coagulation factor preparations. For perioperative management 
using extended half-life drugs, we consider that further case studies are necessary to 
prepare dosing regimens. However, such drugs have the potential to impact not only 
periodic replacement therapy but also perioperative management in hemophilia 
patients. For the reasons stated above, we feel that the extended half-life drugs have 
the potential to significantly impact hemophilia treatment.
15.  Possibility of subcutaneously injectable coagulation factor 
preparations
Another recent advancement in hemophilia drugs is the development of a 
subcutaneously injectable formulation, which overcomes the need for intravenous 
injection. The common name of this drug is emicizumab, and the trade name is 
HEMLIBRA®. The efficacy of emicizumab is characterized as “suppression of 
bleeding tendency in congenital factor VIII-deficient patients positive for inhibitors 
against factor VIII.” As with other factor VIII drugs and bypass medicines, there 
are no indications for administration during perioperative period or during sudden 
bleeding events, and increase in blood emicizumab levels is disallowed. Currently, 
this drug has been formulated as an intravenous injection and is being used for sud-
den bleeding events or during surgery in patients who undergo prophylactic replace-
ment therapy with subcutaneous coagulation factor preparations. In the future, it is 
expected that this drug will also be recommended for use in hemophilia patients who 
are negative for factor VIII inhibitors. However, currently, this drug is being admin-
istered only to patients positive for factor VIII inhibitors. Phase III clinical trials of 
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the use of emicizumab in surgical cases have been conducted, but the subjects have 
been limited to those positive for factor VIII inhibitors. Literature evidence of the 
use of emicizumab during surgery in patients without inhibitors is lacking, and thus 
comparative assessments cannot be made. There is also no evidence regarding the use 
of this drug during time of surgery in patients with inhibitors as well. As described 
above, there is little evidence to support the efficacy of emicizumab administration 
in perioperative period, and further studies are indicated.
16. Treatment of hemophiliac patients with inhibitors
16.1 Outline
Inhibitors are anti-factor VIII or anti-factor IX allogeneic antibodies gener-
ated against factor VIII and factor IX in pharmaceutical preparations as a result of 
replacement therapy with coagulation factor preparations. When an inhibitor gen-
erates, it binds to factor VIII and factor IX, resulting in structural and functional 
abnormalities. Furthermore, as the clearance is increased by the formation of the 
antigen-antibody complex, the hemostatic effect of replacement therapy drastically 
decreases/disappears [13]. Hemostasis therapy is roughly divided into neutraliza-
tion therapy and bypass hemostasis therapy. And it is chosen mainly based on the 
severity of bleeding symptoms, the potency and reactivity of the inhibitor, and past 
medical history.
16.2 Inhibitor phenotype
Inhibitors are measured by Bethesda method [14] based on coagulation single step 
method. The amount of antibody that inactivates factor VIII or factor IX contained in 
1 ml of normal plasma by 50% is defined as 1 Bethesda Unit/ml (BU/ml). Normally, 
>0.6 BU/ml is judged to be positive for inhibitors. In particular, the Nijmegen method 
is recommended for measurements around 1 BU/ml [15]. Inhibitor titers are defined 
as high titer ≧ 5 BU/ml and low titer <5 BU/ml. A high responder (HR) is defined as 
a case in which an inhibitor of ≧5 BU/ml in the Factor VIII/IX Subcommittee of the 
International Conference on Thrombosis and Hemostasis. And it is recommended that 
<5 BU/ml case be defined as low responder (LR) [16]. Inhibitor titers may jump sharply 
5–7 days after preparation administration. This is called an anamnestic response. The 
Japan Society of Thrombosis and Hemostasis Academic Standardization Committee 
Hemophilia Subcommittee advocates an algorithm for selecting therapeutic prepara-
tions depending on the potency of the inhibitor and either HR or LR.
17. Replacement therapy
17.1 Selection criteria for replacement therapy and dosage
The first choice of low titer (<5 BU/ml) inhibitor holding LR with no anamnestic 
response in the past is a continuation of replacement therapy [17]. To obtain a 
definite hemostatic effect, add the necessary formulation for inhibitor neutraliza-
tion and target hemostatic level. The neutralization amount (unit) is theoretically 
calculated as 40 × weight (kg) × {[100 hematocrit value (%)]/100} × inhibitor titer 
(BU/ml). Depending on the inactivation pattern of the anti-factor VIII or anti-IX 
factor activity of the inhibitor, it may not necessarily rise as expected. Therefore, 
monitoring of coagulation factor activity is desired. Bypass hemostasis therapy 
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described later is the first choice for HR types that have elevated ≧ 5 BU/ml in the 
past even at <5 BU/ml, but in case of severe bleeding symptoms or major surgery, 
replacement therapy is selected. However, in the case of HR, it is practical to plan a 
hemostasis therapy after the reaction, taking into consideration the appearance of 
previous immune response after 5–7 days after administration. Usually change to 
bypass hemostasis therapy. Even when the inhibitor titer is 5–10 BU/ml, it is pos-
sible to carry out neutralization therapy with high volumes of Factor VIII and Factor 
IX preparation at severe bleeding and major surgery.
17.2 Selection of replacement therapy preparation
There are three types of factor VIII (FVIII) preparations that can be used in 
Japan. They are plasma-derived factor VIII formulation, genetically modified 
factor VIII, and plasma-derived factor VIII (FVIII)/von Willebrand factor (VWF) 
complex preparation. There are two types of factor IX preparation that can be used: 
plasma-derived preparations and recombinant preparations. In some hemophilia A 
inhibitor cases, it is known that the hemostatic effect of the FIII/VWF preparation 
exceeds that of the factor VIII preparation. It is clarified that this inhibitor is an 
antibody which recognizes the factor VIII light chain and suppresses FVIII/VWF 
binding, and reactivity to FVIII is decreased by the presence of VWF [18].
17.3 Method of administration of preparation
Normally, factor VIII preparation and factor IX preparation are administered in 
bolus, but continuous administration is also selected at severe bleeding and hemo-
static management of major operation. There are no standards for dose administra-
tion in inhibitor cases. If the inhibitor is completely neutralized by the initial bolus 
administration, the coagulation factor activity can theoretically be maintained 
in the administration example similar to the cases without inhibitor. In practice, 
however, higher doses are often required.
18. Bypass hemostatic therapy
According to the guidelines published by the Japan Thrombosis Hemorrhagic 
Society, the first choice when the inhibitor titer ≧ 5 BU/ml is bypass hemostasis 
therapy except severe bleeding symptoms and hemostasis management during 
major surgery [17]. Traditionally, activated prothrombin complex concentrates 
(aPCC) or prothrombin complex concentrates (PCC) were the main body of bypass 
hemostasis therapy, but bypass hemostasis therapy has greatly advanced after the 
introduction of genetically modified active factor VII factor formulation (rFVIIa). 
Sales of PCC preparations adapted for inhibitors have been discontinued. Currently 
available bypass preparations are three, aPCC (FEIBA®), rFVIIa (NovoSeven®), 
and blood coagulation factor X factor-activated factor VII (Byclot®).
18.1 Bypass hemostatic therapy preparation
18.1.1 Activated prothrombin complex concentrates (aPCC)
18.1.1.1 Hemostasis management during surgery by aPCC
Conventionally, it was extremely difficult for a variety of reasons to per-
form hemostasis management at the time of surgery of HR inhibitor cases with 
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inhibitors of high titer by only aPCC. The main reasons are the uncertainty of the 
hemostatic effect, expensive medical expenses, thrombosis, and fear of onset of 
disseminated intravascular coagulation syndrome (DIC), and furthermore, the 
evidence is low. Many of the cases used aPCC in combination after neutralization 
therapy with factor VIII and factor IX preparations. However, in conjunction with 
the increase in patients undergoing surgery by rFVIIa, reports on practical cases 
with only aPCC have been increasing in recent years. According to a multicenter 
retrospective study by Negrier et al., aPCC was used for 19 small surgical proce-
dures [19]. The most frequent cases were joint puncture (10 cases), the number 
of doses was two to six times, and the administration days were in the range of 
2–4 days, both of which were effective. The dose was 78–160 units/kg/day. Four 
cases were used for tooth extraction, three cases were administered twice, one 
case was administered six times, and the administration period was, respectively, 
1 day and 3 days. Four cases were performed in major surgery. The breakdown was 
knee joint synovectomy, knee arthroplasty, skin muscle formation, and prosta-
tectomy. The dose and duration of aPCC during major surgery differ depending 
on the operation name. The dose is 120–210 units/kg/day and the administration 
period is 5–21 days. The dosing regimen after surgical treatment such as subcu-
taneously implanted central intravenous catheterization procedure ranged from 
50 to 74 units/kg one to two times/day; dosing days ranged from 1 to 6 days [20]. 
In Japan, since aPCC had limitation of use (inhibitor potency ≥10 BU/ml, within 
3 days of administration), experience of using aPCC in major surgery is small. 
Since these restrictions have been removed since 2008, surgical therapy using 
aPCC in Japan could be considered. The number of cases is still small internation-
ally, and it is necessary to standardize on the aPCC administration regimen at the 
time of surgery in the future.
18.1.1.2 Anamnestic response by aPCC
A fragment of factor VIII is detected in aPCC. Therefore, there are cases in 
which inhibitor titers are increased by repeated administration of aPCC. This 
is because aPCC contains the light chain fragment of factor VIII, and it is 
common in inhibitors of the light chain recognition type in particular [21]. 
Therefore, in cases that the inhibitor titer does not decrease and the high value 
is sustained, it is necessary to pay attention to the anamnestic response caused 
by aPCC. Incidentally, even in cases with this history of reaction, there are cases 
in which they subsequently decline as a result. In the report of Negrier et al., 
anamnestic response was seen in 31.5% of the patients, but of which 64.7% had 
gradually decreased [19].
18.1.2 rFVIIa
18.1.2.1 Hemostasis management during surgery by rFVIIa
rFVIIa is being used not only for small surgical operations but also for moderate 
or more surgical operations. Lusher et al. collected results on 103 surgical operations 
totaling 21 cases of major operation, 57 cases of small operation, and 25 cases of 
suturing relation [22]. According to the report, effective cases were 81, 86 and 92%, 
respectively, indicating that major surgery is also possible with hemostasis manage-
ment by rFVIIa. Even in Japan, there are no restrictions on insurance medical treat-
ment, so we have used more experience than aPCC and the number of cases such as 
large orthopedic surgery including artificial joint replacement surgery is increasing. 
Schrarer et al. recommended that 90 μg/kg every 2–3 days for 1–2 days, in large 
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surgery, and, in small surgery, the same amount of administration every 2–4 hours, 
every 6–7 days and every 6–8 hours 2 weeks [23]. Rodriguez et al. collected 108 cases 
of orthopedic surgical cases with inhibitor and reported the usefulness of rFVIIa 
[24]. Eighty cases of orthopedic surgical cases were collected over the period from 
2000 to 2006. The initial dose was 120 μg/kg and thereafter administration of 90 μg/
kg every 2 hours or 50 μg/kg/hour in continuous administration. Obergfell et al. 
reported that this regimen is useful [25]. In Japan’s guidelines, as in the case of severe 
bleeding hemostasis therapy, administration is performed every 2 hours for 1–2 days 
at the time of major operation. Thereafter, they recommend a regimen that gradually 
extends the dosing interval, for example, every 3, 4, 8, and 12 hours [17]. Because 
of its short half-life and the fact that thrombin burst is caused by high concentration 
of FVIIa is considered to be the basis of hemostatic effect, bolus administration is 
recommended in principle for administration of rFVIIa. However, there are increas-
ing reports that sustained administration therapy is useful, especially when frequent 
administration is required as in surgical operation [26, 27]. In general administration 
method, continuous administration is started at 14–16.5 μg/kg/hour after the initial 
bolus administration of 90–120 μg/kg. Thereafter, the factor VII activity (FVII:C) is 
administered so as to maintain at least 10 units/ml. However, Ludlam et al. recently 
encouraged maintaining the trough level of FVII:C at 30 units/ml at a dose of 50 μg/
kg/h during major surgery [28].
18.1.3 Mixture of plasma-derived factor VIIa and factor X (MC710)
MC710 is a plasma-derived new bypass hemostatic therapeutic agent developed 
in Japan, because the effect of FVIIa is enhanced and sustained due to the coexis-
tence of FX (FVIIa:FX = 1:10). According to pharmacodynamic analysis by coagula-
tion waveform analysis conducted in Phase I study, activated partial thromboplastin 
time (APTT), maximum solidification rate, and maximum coagulation acceleration 
peaked 10 minutes after MC 710 administration. And it was before administration 
level 12 hours after administration. Although the enhancing effect of MC710 was 
not concentration dependent, it was higher than 120 μg/kg of rFVIIa or 50/75 U/kg 
of aPCC at dose>80 μg/kg [29]. Furthermore, in Phase II clinical trials, efficacy and 
safety were examined at two doses of 60 μg/kg and 120 μg/kg in patients with inhibi-
tors of six cases. The hemostasis effect was effective and remarkable 8 hours after 
administration in total nine bleeding episodes. There were no side effects attribut-
able to the formulation [30].
19. Selection of bypass hemostatic therapy preparation
Both current bypass treatment formulations, aPCC and rFVIIa, have been clari-
fied for efficacy in hemostatic therapy for acute bleeding and surgical treatment. 
However, as to selection of both formulations, it is necessary to comprehensively 
select the presence/absence of anamnestic response in the past, the risk of throm-
bosis, and past hemostatic effect. It was revealed that the hemostasis effect between 
a single dose of aPCC (75–100 Units/kg) and two doses of rFVIIa (90–120 μg/kg) 
is equivalent to the hemorrhage of the joint [31]. Interestingly, however, cases were 
found in which there was a difference in hemostatic effect among the preparations. 
Even in the same case, the difference in the hemostatic effect between both prepara-
tions suggests that it is necessary to change to multiple drugs when the first choice 
preparation is ineffective [32]. For the selection of preparations at the time of sur-
gery, it has been reported that preparations are added ex vivo to the patient’s plasma 
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prior to surgery and the hemostatic effect is judged by rotation thromboelastometry 
(ROTEM) before operation [33].
20. Bypass hemostatic therapy in special case
20.1 Cases before immune tolerance induction (ITI therapy)
Regarding the effectiveness of ITI therapy, the only statistically proven factor is 
the potency of the inhibitor at the beginning of ITI. Therefore, the lower the inhibi-
tor titer, the higher the success rate. Recent international clinical studies of ITI also 
target <10 BU/ml patients [34]. As a rule, rFVIIa is the first choice in cases where 
anamnestic response occurs with aPCC administration.
20.2 Cases with a history of allergic symptoms
Some patients with hemophilia B with some inhibitors have allergic symptoms 
for the preparation containing factor IX. Allergic symptoms are often severe and 
may present anaphylaxis. The essence of allergic symptoms is anti-IX factor IgG 
(immunoglobulin G), which is said to be particularly IgG1 antibody [35]. The aPCC 
preparation contains factor IX. Patients who are allergic to factor IX preparation 
may have similar symptoms to aPCC. For such cases, it is also possible to desensitize 
by administering a preparation containing factor IX in small amounts [36]. In 
general, however, the first choice in cases with allergic history is rFVIIa and MC710.
21. Conclusion
Here we summarize the various options available for the perioperative man-
agement of patients with hemophilia and also discuss joint surgery, which is an 
important aspect of treatment of patients with hemophilia. Unlike healthy subjects, 
patients with hemophilia require special perioperative management. We hope that 
this manuscript will help in formulating better treatment of patients with hemo-
philia in the future.
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